MEREO BIOPHARMA GROUP PLC ADR reports a Return on Equity (ROE) of -104.83%.

What is MREO's dividend yield?

MEREO BIOPHARMA GROUP PLC ADR offers a dividend yield of 0.00%.

What is MREO's Deepscope Quality Score?

Deepscope rates MREO's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy MREO?

Deepscope's AI Timing Score for MREO is 50 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does MREO belong to?

MEREO BIOPHARMA GROUP PLC ADR is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

MREO (NASDAQ) 株価分析 | MEREO BIOPHARMA GROUP PLC ADR

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-05 | FS: 2026-03-31)

MREO

MEREO BIOPHARMA GROUP PLC ADR

US:NASDAQ STOCK Healthcare >> Biotechnology News 59

USD 0.31

-0.00 (-1.51%) Day Change

Watchlist Portfolio Compare Chart

0.19

D/E

-104.8%

ROE

-87.9%

ROA

0.00%

Div Yield

MEREO BIOPHARMA GROUP PLC ADR
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.31 Price -0.00 (-1.51%) Day Change	NEWS SCORE: 59

MREO, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Deepscope 分析

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	59
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.31
PBV / Sector	1.49 / 4.63 GOOD
Earning Per Share	-0.22

PE / Sector	N/A / 17.43
PEG or PE/Growth / Sector	N/A / 0.53
Average 1M Daily Value	2.13 M GREAT
Average 1W Daily Value	1.60 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-7,139.75 / 449.48
NPM Average (%) / Sector	-4,651.27 / -1,506.49
NPM Change Average (%) / Sector	N/A / 4,940.99
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-87.90 / 30.58
ROA Average (%) / Sector	-66.89 / -347.17
ROA Change Average (%) / Sector	16.67 / 5,125.52 GOOD
ROE (%) / Sector	-104.83 / -3.58
ROE Average (%) / Sector	-83.68 / 40.65
ROE Change Average (%) / Sector	9.88 / 2,109.80
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 4.17

登録情報

Analyze Date	2026-06-06 09:09:03
Symbol	MREO
Name	MEREO BIOPHARMA GROUP PLC ADR
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	159.62 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	50.76 / 8,857.28

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: One Cavendish Place, London, United Kingdom, W1G 0QF

Phone: 44 33 3023 7300

Website: https://www.mereobiopharma.com

Sector: Healthcare >> Biotechnology

Description: Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.